The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
5 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $12,271,848 in first-year total cost, median $2,520,000.
Most frequent study sections
- Special Emphasis Panel[ZAI1 JBS-A (S1)]2
- Special Emphasis Panel[ZAI1 JRR-A (S1)]2
- Special Emphasis Panel[ZAI1 RB-A (S1)]1
Most frequent institutions
- DUKE UNIVERSITY2
- BETH ISRAEL DEACONESS MEDICAL CENTER1
- OREGON HEALTH & SCIENCE UNIVERSITY1
- TEXAS BIOMEDICAL RESEARCH INSTITUTE1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2019 | Messenger RNA Immunogens for initiation of protective HIV non-neutralizing antibodies1U19AI142596-01 | HAYNES, BARTON F. | DUKE UNIVERSITY, NC | $3,659,615 | ZAI1 |
| 2019 | Cold Chain-Independent, Needle-Free Mucosal Virosomal Vaccine to Prevent HIV-1 Acquisition at Mucosal Levels1U19AI142636-01 | EDWARDS, DONALD BRUCEFLEURY, SYLVAIN | TEXAS BIOMEDICAL RESEARCH INSTITUTE, TX | $1,213,216 | ZAI1 |
| 2018 | Development of Ad26/Env Vaccines for HIV1U19AI128751-01A1 | BAROUCH, DAN H. | BETH ISRAEL DEACONESS MEDICAL CENTER, MA | $2,800,000 | ZAI1 |
| 2018 | Messenger RNA immunogens for initiation of HIV V3-glycan neutralizing B cell lineages1U19AI135902-01 | HAYNES, BARTON F. | DUKE UNIVERSITY, NC | $2,079,017 | ZAI1 |
| 2017 | Development of Immunogenicity- and Efficacy-Optimized CMV Vectors for an HIV/AIDS Vaccine1U19AI128741-01 | PICKER, LOUIS J. | OREGON HEALTH & SCIENCE UNIVERSITY, OR | $2,520,000 | ZAI1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.